Skip to main content
Bruce Stambler, MD, Cardiology, Atlanta, GA

Bruce S Stambler MD

Adult Congenital Heart Disease, Cardiac Electrophysiology


Professor, Medicine, Case Western Reserve Univ Sch of Med

Join to View Full Profile
  • 275 Collier Rd NWSte 500Atlanta, GA 30309

  • Phone+1 216-844-8500

  • Fax+1 404-351-5983

Dr. Stambler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 1987 - 1990
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1984 - 1987
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1984

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2014 - 2026
  • OH State Medical License
    OH State Medical License 1998 - 2016
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Cardiovascular Disease
    American Board of Internal Medicine Cardiovascular Disease
  • Clinical Cardiac Electrophysiology
    American Board of Internal Medicine Clinical Cardiac Electrophysiology

Awards, Honors, & Recognition

  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Nasal Spray Shows Potential for Quickly Treating ArrhythmiaJuly 2018

Press Mentions

  • Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022
    Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022October 25th, 2022
  • Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia
    Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular TachycardiaOctober 17th, 2022
  • Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update
    Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate UpdateAugust 10th, 2022
  • Join now to see all

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: